123 related articles for article (PubMed ID: 11459209)
1. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Zhou S; Kestell P; Tingle MD; Ching LM; Paxton JW
Cancer Chemother Pharmacol; 2001 Jun; 47(6):541-4. PubMed ID: 11459209
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
Kestell P; Zhao L; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM
Cancer Chemother Pharmacol; 2000; 46(2):135-41. PubMed ID: 10972483
[TBL] [Abstract][Full Text] [Related]
4. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Zhou S; Kestell P; Paxton JW
Drug Metab Rev; 2002 Nov; 34(4):751-90. PubMed ID: 12487149
[TBL] [Abstract][Full Text] [Related]
5. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
Zhou SF; Tingle MD; Kestell P; Paxton JW
Xenobiotica; 2002 Feb; 32(2):87-107. PubMed ID: 11868972
[TBL] [Abstract][Full Text] [Related]
6. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S; Kestell P; Baguley BC; Paxton JW
Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
[TBL] [Abstract][Full Text] [Related]
7. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
[TBL] [Abstract][Full Text] [Related]
8. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
Zhou S; Chin R; Kestell P; Tingle MD; Paxton JW
Br J Clin Pharmacol; 2001 Aug; 52(2):129-36. PubMed ID: 11488768
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
10. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
Kestell P; Paxton JW; Rewcastle GW; Dunlop I; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):323-30. PubMed ID: 10071984
[TBL] [Abstract][Full Text] [Related]
11. Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zhou S; Kestell P; Baguley BC; Paxton JW
Biochem Pharmacol; 2003 Jun; 65(11):1853-65. PubMed ID: 12781337
[TBL] [Abstract][Full Text] [Related]
12. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Chung F; Wang LC; Kestell P; Baguley BC; Ching LM
Cancer Chemother Pharmacol; 2004 May; 53(5):377-83. PubMed ID: 15060740
[TBL] [Abstract][Full Text] [Related]
13. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
Zhou S; Paxton JW; Kestell P; Tingle MD
J Pharm Pharmacol; 2001 Apr; 53(4):463-71. PubMed ID: 11341362
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
15. Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.
Zhou S; Kestell P; Paxton JW
J Pharm Pharmacol; 2002 Jul; 54(7):997-1003. PubMed ID: 12162720
[TBL] [Abstract][Full Text] [Related]
16. Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
Zhou S; Kestell P; Paxton JW
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Sep; 776(2):231-6. PubMed ID: 12138005
[TBL] [Abstract][Full Text] [Related]
17. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
Zhou SF; Paxton JW; Tingle MD; Kestell P; Jameson MB; Thompson PI; Baguley BC
Xenobiotica; 2001 May; 31(5):277-93. PubMed ID: 11491389
[TBL] [Abstract][Full Text] [Related]
18. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
[TBL] [Abstract][Full Text] [Related]
19. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Chung F; Liu J; Ching LM; Baguley BC
Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
[TBL] [Abstract][Full Text] [Related]
20. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR
Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
